<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143388</url>
  </required_header>
  <id_info>
    <org_study_id>CCRT-AC-LAHR-NPC</org_study_id>
    <nct_id>NCT02143388</nct_id>
  </id_info>
  <brief_title>Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial</brief_title>
  <official_title>Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhao Chong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an randomized controlled, multicenter clinical trial. The purpose of this study is to
      evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with or without
      capecitabine as adjuvant chemotherapy in local advanced high risk nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>18 months</time_frame>
    <description>Defined as the time in months from first dose of cisplatin until PD is observed or death occurs due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the acute toxicity with CTC 3.0 when concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy is used.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Three-year locoregional relapse free survival rate</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Three-year distance metastasis free survival rate</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Three-year overall survival rate</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the late toxicity with the RTOG/EORTC criterion when concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy is used.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Local Advanced High Risk Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiation + adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent chemoradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMRT combine with cisplatin concurrent chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMRT combine with cisplatin concurrent chemotherapy</intervention_name>
    <description>Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.</description>
    <arm_group_label>Concurrent chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy</intervention_name>
    <description>Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.</description>
    <arm_group_label>Concurrent chemoradiation + adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III)

          -  Clinical stage III~IVb(UICC 7th)

          -  Meet at least one factor below :1 primary tumor SUVmax&gt;10 in 18F-FDG PET/CT;2 primary
             tumor volume＞30cm3;3 mutiple metastatic cervical lymph node with at least one's short
             diameter＞4cm; 4 T4N2M0; 5 T1-4N3M0;6 EBV-DNA＞2×10E4 copy/l

          -  Range from 18～70 years old

          -  WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L

          -  ALT or AST ＜ 2.5×ULN、bilirubin ＜ 1.5×ULN

          -  OSerum creatinine ＜ 1.5×ULN

        Exclusion Criteria:

          -  Central nervous system metastases

          -  Suitable for local treatment

          -  Uncontrolled seizure disorder or other serious neurologic disease

          -  Clinically significant cardiac or respiratory disease

          -  Drug or alcohol addition

          -  Do not have full capacity for civil acts

          -  Severe complication, active infection

          -  Concurrent immunotherapy or hormone therapy for other diseases

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhao chong, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shen guanzhu, M.D</last_name>
    <phone>+86-13427529949</phone>
    <email>shenguanzhu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao chong, M.D</last_name>
      <phone>+86-13902206160</phone>
      <email>zhaochong@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.org.cn</url>
    <description>Home Page of Cancer Center, Sun Yat-sen University</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhao Chong</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Local advanced</keyword>
  <keyword>high risk</keyword>
  <keyword>nasopharyngeal carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

